Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: A 1-year naturalistic follow-up study

Journal of Clinical Psychopharmacology

Volumn 29, Issue 4, 2009, Pages 394-396

  Takeuchi, Hiroyoshi ^a   Uchida, Hiroyuki ^a,b,c   Suzuki, Takefumi ^a,d   Watanabe, Koichiro ^a   Kashima, Haruo ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Inokashira Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; OLANZAPINE; RISPERIDONE;

AUDITORY HALLUCINATION; CLINICAL GLOBAL IMPRESSION SCALE; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; FOLLOW UP; HOSPITAL PATIENT; HUMAN; LETTER; OUTPATIENT; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 68449093823     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181accfec     Document Type: Letter

References (7)

1. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
2. Takeuchi H, Suzuki T, Uchida H, et al. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol. 2008;28:540-543.
3. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
4. WHO. Collaborating Centre for Drug Statistics Methodology. Available at: http://www.whocc.no/atcddd/. Accessed August 6, 2008.
5. Inagaki A, Inada T, Fujii Y. Dose equivalents of psychotropic drugs [in Japanese]. Tokyo: Seiwa Press; 1999.
6. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology. 2000;152:174-180.
7. Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry. 2006;67:1942-1947.